Lymph-Node Targeted Peptide Vaccination Promotes mKRAS-Specific T Cell Immunity & Enhances TCR-T Cell Therapy Against Solid Tumors

Time: 12:30 pm
day: Day One Track A


  • The AMP platform enables enhanced lymph node delivery of peptide immunogens and molecular adjuvants to potently stimulate T cell immunity
  • AMP-vaccination promotes expansion and functional enhancement of endogenous and adoptively transferred mKRAS-specific T cells in vitro and in vivo
  • AMP-vaccine combination with TCR-T cell therapy promotes anti-tumor efficacy in vivo